GlassScriptPhysician profile
Timothy James Horrigan
NPI 1245333848
$9,067.05
in general payments reported to CMS, 2019-2025
40 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $1,275 · 2021: $1,436 · 2022: $1,496 · 2023: $1,079 · 2024: $1,439 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,643.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,099.30 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $963.17 | 2019-2025 | |
| Novo Nordisk INC | $676.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $657.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $603.38 | 2021-2025 | |
| Grifols USA, LLC | $486.10 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.59 | 2019-2024 | Jardiance, Tradjenta, Ofev |
| Janssen Pharmaceuticals, INC | $370.32 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $366.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $357.18 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $340.19 | 2019-2022 | |
| Esperion Therapeutics, INC. | $244.60 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $232.51 | 2020-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $204.88 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $192.04 | 2019-2025 | Eliquis |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Horrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.